多发性骨髓瘤患者血清胱抑素C的检测及其临床意义  

Detection and clinical significance of serum cystatin C in multiple myeloma patients

作　　者：熊丹[1] 李末娟 李庆华[1] 梁亮[1] 吴东红[1] 

机构地区：[1]广东医学院附属医院血液内科,524000 [2]湛江市第二人民医院

出　　处：《中国实用医药》2016年第18期10-11,共2页China Practical Medicine

摘　　要：目的探讨多发性骨髓瘤患者血清胱抑素C水平变化的临床意义。方法 92例初治多发性骨髓瘤患者作为观察组,92例健康体检者作为对照组,比较未治疗前两组血清胱抑素C、β_2-微球蛋白、白蛋白水平及其中28例多发性骨髓瘤患者治疗达完全缓解后血清胱抑素C、β_2-微球蛋白的水平变化。结果未治疗前观察组血清胱抑素C、β_2-微球蛋白水平显著高于对照组(P<0.05),白蛋白水平显著低于对照组(P<0.05);治疗后达到完全缓解的28例患者血清胱抑素C、β_2-微球蛋白水平较治疗前均显著下降(P<0.05)。结论血清胱抑素C与多发性骨髓瘤肿瘤负荷密切相关,其检测水平高低对多发性骨髓瘤临床治疗的疗效评价及预后判断具备很好的参考价值。Objective To investigate clinical significance of changed serum cystatin C in multiple myeloma patients. Methods There were 92 early multiple myeloma patients as observation group and 92 healthy people as control group. Comparison was made on serum cystatin C, β2-microglobulin, albumin level in both groups before treatment, and changed serum cystatin C and β2-microglobulin levels in 28 complete remission cases after treatment. Results Before treatment, the observation group had obviously higher serum cystatin C and β2-microglobulin levels（P〈0.05）, and lower albumin level than the control group（P〈0.05）. All 28 complete remission cases after treatment had much lower serum cystatin C and β2-microglobulin levels than those before treatment（P〈0.05）. Conclusion Due to its close correlation with multiple myeloma load, detection of serum cystatin C contains highly referring value for curative effect evaluation and prognosis judgment for multiple myeloma.Key words

关 键 词：多发性骨髓瘤 血清胱抑素C Β2-微球蛋白 

分 类 号：R733.3[医药卫生—肿瘤]